Physician profile
Scott Daniel Barkin
NPI 1841282969
$2,013.20
in general payments reported to CMS, 2019-2025
27 companies · $228 in 2025
The $228 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $978 · 2020: $26.28 · 2021: $88.37 · 2022: $107 · 2023: $512 · 2024: $74.08 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $779 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $779.31 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $1,134.73 | 2019-2023 | Aquabeam Robotic System |
| Astellas Pharma US INC | $128.91 | 2019-2023 | Myrbetriq |
| Laborie Medical Technologies Corp. | $81.11 | 2024-2025 | Optilume Bph Drug Coated Balloon Catheter |
| Myriad Genetic Laboratories, INC. | $60.92 | 2023-2025 | Prolaris |
| Abbvie INC. | $57.26 | 2024-2025 | |
| Myovant Sciences INC. | $51.19 | 2021 | |
| Endo Pharmaceuticals INC. | $50.71 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $43.44 | 2023-2024 | Gemtesa |
| Olympus America INC. | $36.22 | 2023-2025 | Itind System |
| Astrazeneca Pharmaceuticals Lp | $35.06 | 2025 | Imfinzi |
| Axonics, INC. | $33.80 | 2022-2023 | Axonics |
| Novo Nordisk INC | $32.12 | 2025 | Rivfloza |
| Boston Scientific Corporation | $31.55 | 2019-2022 | |
| Neotract INC. | $29.65 | 2019 | |
| Genzyme Corporation | $25.60 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| 180 Medical, INC. | $23.39 | 2019 | |
| Dendreon Pharmaceuticals LLC | $20.07 | 2019 | |
| Teleflex LLC | $17.78 | 2023 | Urolift |
| Endo USA, INC. | $17.62 | 2025 | Xiaflex, Aveed |
| Medtronic USA, INC. | $16.51 | 2019 | |
| Coloplast Corp | $15.62 | 2019 | |
| Calyxo, INC. | $15.54 | 2023 | Cvac Aspiration System |
| Urogen Pharma, INC. | $14.60 | 2025 | |
| Idorsia Pharmaceuticals US INC | $13.89 | 2023 | Quviviq |
| Medtronic, INC. | $13.55 | 2025 | Interstim |
| Glaxosmithkline, LLC. | $12.36 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,485.75 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Barkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.